Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus CLEVIPREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus CLEVIPREX.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs CLEVIPREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker